Identification of novel germline polymorphisms governing capecitabine sensitivity.
O'Donnell PH, Stark AL, Gamazon ER et al.
Publication Details
Comprehensive information about this research publication
Abstract
Summary of the research findings
Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use.
Up to 84 East Asian ancestry lymphoblastoid cell lines, up to 164 European ancestry lymphoblastoid cell lines, up to 173 African ancestry lymphoblastoid cell lines, up to 82 African American lymphoblastoid cell lines
Study Statistics
Key metrics and study information
Analysis
Comprehensive review of health and genetic findings
Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.
Analysis In Progress
Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.